UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (132421) 132421
Newsletter (2089) 2089
Newspaper Article (1464) 1464
Book Chapter (856) 856
Magazine Article (307) 307
Patent (209) 209
Dissertation (138) 138
Book / eBook (121) 121
Reference (55) 55
Government Document (49) 49
Transcript (44) 44
Trade Publication Article (27) 27
Book Review (22) 22
Conference Proceeding (20) 20
Web Resource (16) 16
Publication (11) 11
Streaming Video (7) 7
Report (4) 4
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (109825) 109825
humans (101635) 101635
life sciences & biomedicine (101456) 101456
female (51858) 51858
male (49013) 49013
animals (39495) 39495
middle aged (29095) 29095
adult (29049) 29049
oncology (23569) 23569
genetic aspects (23523) 23523
research (22764) 22764
aged (20269) 20269
health aspects (18331) 18331
mice (18050) 18050
care and treatment (17117) 17117
cancer (16600) 16600
risk factors (15366) 15366
analysis (14943) 14943
gene expression (14789) 14789
treatment outcome (14367) 14367
mutation (12735) 12735
pharmacology & pharmacy (11610) 11610
genetics (11328) 11328
medicine, research & experimental (11298) 11298
research & experimental medicine (11284) 11284
medicine (11197) 11197
research article (10916) 10916
genetics & heredity (10817) 10817
proteins (10141) 10141
genotype (9843) 9843
adolescent (9706) 9706
abridged index medicus (9431) 9431
physiological aspects (9379) 9379
prognosis (9033) 9033
cell biology (9011) 9011
drug therapy (8696) 8696
hematology (8695) 8695
medicine & public health (8668) 8668
biochemistry & molecular biology (8552) 8552
patients (8519) 8519
genes (8472) 8472
immunology (8399) 8399
science & technology - other topics (8207) 8207
studies (8186) 8186
child (8126) 8126
multidisciplinary sciences (7848) 7848
young adult (7731) 7731
medical research (7662) 7662
disease models, animal (7611) 7611
chemotherapy (7222) 7222
apoptosis (7211) 7211
aged, 80 and over (6972) 6972
tumors (6943) 6943
development and progression (6906) 6906
biotechnology & applied microbiology (6585) 6585
rats (6533) 6533
science (6448) 6448
cell line, tumor (6429) 6429
gene therapy (6428) 6428
neurosciences & neurology (6321) 6321
clinical trials (6089) 6089
rodents (6006) 6006
genetic research (5991) 5991
time factors (5948) 5948
review (5690) 5690
genetic predisposition to disease (5685) 5685
surgery (5582) 5582
retrospective studies (5555) 5555
signal transduction (5533) 5533
inflammation (5521) 5521
pharmacogenetics (5375) 5375
usage (5298) 5298
neurosciences (5290) 5290
breast cancer (5235) 5235
kinases (5194) 5194
mice, inbred c57bl (5153) 5153
cardiovascular system & cardiology (5086) 5086
stem cells (5063) 5063
pregnancy (5030) 5030
biology (4917) 4917
child, preschool (4887) 4887
transplantation (4837) 4837
diagnosis (4774) 4774
cancer therapies (4763) 4763
antineoplastic agents - therapeutic use (4736) 4736
deoxyribonucleic acid--dna (4719) 4719
pharmacology (4704) 4704
genetic structures (4649) 4649
pediatrics (4627) 4627
internal medicine (4622) 4622
metastasis (4570) 4570
phenotype (4531) 4531
polymorphism, single nucleotide (4423) 4423
enzymes (4398) 4398
polymerase chain reaction (4337) 4337
biomarkers (4314) 4314
medicine, experimental (4295) 4295
polymorphism, genetic (4287) 4287
genetic disorders (4286) 4286
general & internal medicine (4261) 4261
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (28) 28
Online Resources - Online (15) 15
Collection Dvlpm't (Acquisitions) - Vendor file (7) 7
Media Commons - Microtexts (5) 5
UofT at Mississauga - Stacks (3) 3
UofT at Scarborough - Stacks (3) 3
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (2) 2
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Gerstein Science - Theses (1) 1
Law (Bora Laskin) - Stacks (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Women's College Hospital - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (136367) 136367
Japanese (574) 574
French (513) 513
German (430) 430
Chinese (289) 289
Spanish (216) 216
Portuguese (213) 213
Russian (165) 165
Italian (60) 60
Norwegian (60) 60
Hungarian (50) 50
Polish (47) 47
Dutch (35) 35
Danish (30) 30
Turkish (30) 30
Swedish (29) 29
Czech (22) 22
Korean (21) 21
Finnish (14) 14
Serbian (9) 9
Croatian (8) 8
Hebrew (7) 7
Arabic (6) 6
Ukrainian (6) 6
Romanian (5) 5
Icelandic (3) 3
Slovak (3) 3
Afrikaans (2) 2
Indonesian (2) 2
Bulgarian (1) 1
Lithuanian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The oncologist (Dayton, Ohio), ISSN 1549-490X, 05/2017, Volume 22, Issue 7, pp. 823 - 833
.... Targeted therapies that inhibit specific steps of the mitogen‐activated protein kinase pathway have been shown to provide significant overall treatment benefit in patients with this difficult‐to‐treat disease... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | Life Sciences & Biomedicine | Oncology | Science & Technology | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Index Medicus | Melanoma and Cutaneous Malignancies
Journal Article
Gastroenterology (New York, N.Y. 1943), ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
... than in treatment-naive patients, and are noticeably lower among prior null responders.4–8 In addition, the toxicity of pegIFN and long duration of therapy (up to 48 weeks... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus
Journal Article
Annals of internal medicine, ISSN 0003-4819, 11/2016, Volume 165, Issue 9, pp. 625 - 634
Journal Article
Annals of internal medicine, ISSN 0003-4819, 07/2015, Volume 163, Issue 1, pp. 1 - 13
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2017, Volume 377, Issue 19, pp. 1813 - 1823
In patients with surgically resected melanoma, those with BRAF mutations who received 1 year of oral adjuvant therapy with dabrafenib and trametinib had a 53... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Oximes - therapeutic use | Male | Adjuvants, Immunologic - adverse effects | Young Adult | Melanoma - genetics | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Double-Blind Method | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Neoplasm Recurrence, Local | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Adolescent | Survival Analysis | Aged | Pyridones - therapeutic use | Melanoma - surgery | Mutation | Neoplasm Staging | Pyridones - adverse effects | Melanoma - mortality | Usage | Relapse | Patient outcomes | Analysis | Melanoma | Adjuvant treatment | Outcome and process assessment (Health Care) | Reports | Drug therapy | Cancer | Diseases | Medical imaging | Oncology | Metastasis | FDA approval | Kinases | Cancer therapies | Survival | Skin cancer | Metastases | Medical prognosis | Immunotherapy | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 11/2009, Volume 27, Issue 33, pp. 5538 - 5546
.... This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
Annals of oncology, ISSN 0923-7534, 03/2018, Volume 29, Issue 3, pp. 646 - 653
Journal Article
The lancet oncology, ISSN 1470-2045, 11/2017, Volume 18, Issue 11, pp. 1467 - 1482
Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand of the MET receptor, hepatocyte growth factor (HGF). We aimed to assess... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Capecitabine - administration & dosage | Prognosis | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Stomach Neoplasms - pathology | Epirubicin - administration & dosage | Cisplatin - administration & dosage | Esophageal Neoplasms - pathology | Dose-Response Relationship, Drug | Antibodies, Monoclonal, Humanized - administration & dosage | Esophageal Neoplasms - mortality | Adult | Stomach Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Esophagogastric Junction - pathology | Proto-Oncogene Proteins c-met - drug effects | Treatment Outcome | Stomach Neoplasms - drug therapy | Proto-Oncogene Proteins c-met - genetics | Disease-Free Survival | Capecitabine - adverse effects | Esophageal Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Survival Analysis | Cisplatin - adverse effects | Aged | Esophageal Neoplasms - drug therapy | Stomach Neoplasms - mortality | Epirubicin - adverse effects | Clinical trials | Monoclonal antibodies | Anthracyclines | Product development | Esophageal cancer | Analysis | Index Medicus
Journal Article
Journal of inherited metabolic disease, ISSN 0141-8955, 3/2013, Volume 36, Issue 2, pp. 385 - 394
Journal Article